Investigational drug · Phase 2
MWN109 4
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "MWN109 4"
First trial start
2026
Jan 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MWN109 4", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus (T2DM)
- Overweight , Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "MWN109 4" as an intervention, largest first.
- Phase 2 Study of MWN109 Tablet in Participants With Overweight or ObesityPivotal-lookingCompleted
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07791524 · 255 participants · Start Jan 5, 2026 · Primary completion Jul 9, 2026
Drug: MWN109 1; MWN109 2 and 3 more · For: Overweight , Obesity
Sites: Luoyang, China
- Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes MellitusPivotal-lookingRecruiting
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07801820 · 240 participants (planned) · Start Jun 23, 2026 · Primary completion Mar 2027
Drug: MWN109 1; MWN109 2 and 4 more · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Beijing, China
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07787611 · 98 participants · Start Jun 27, 2025 · Primary completion Dec 20, 2025
Drug: MWN109 tablet; MWN109 tablet and 1 more · For: Healthy Volunteers
Sites: Kunming, China
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT06859853 · 72 participants (planned) · Start Mar 17, 2025 · Primary completion Sep 25, 2025
Drug: Placebo; Subcutaneous single and mutiple dose · For: Overweight or Obese
Sites: Melbourne, Australia
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT06938269 · 60 participants (planned) · Start Jun 18, 2025 · Primary completion Mar 2026
Drug: MWN109 tablet; Placebo · For: Overweight or Obesity
Sites: Adelaide, Australia; Bayswater, Australia
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07787624 · 48 participants · Start Dec 18, 2024 · Primary completion Jul 20, 2025
Drug: MWN109; MWN109 and 1 more · For: Healthy Volunteers
Sites: Kunming, China
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07787728 · 40 participants · Start Jul 14, 2025 · Primary completion Dec 16, 2025
Drug: MWN109 1; MWN109 2 and 3 more · For: Overweight , Obesity
Sites: Kunming, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Type 2 Diabetes Mellitus (T2DM)
- BofanglutideGZR18, BofanglutidaPhase 311 trials
Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult
- MWN109 1Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 2Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 3Phase 35 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- BGM0504 AdministeredPhase 32 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes Mellitus (T2DM)
- AD-233APhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233BPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233CPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.